Evolus Q4 revenue rises

Evolus

03/03/2026 21:14

Overview

Beauty company reported Q4 revenue up 14% yr/yr, driven by higher product volumes

Company achieved Q4 GAAP operating income of $4.2 mln, reflecting expense management

Outlook

Total net revenues for 2026 projected to be between $327 mln and $337 mln

Non-GAAP operating expenses for 2026 estimated to grow 0% to 3% year-over-year

Company expects low- to mid-single digit adjusted EBITDA margin in 2026

Result Drivers

PRODUCT VOLUME - Q4 revenue growth driven by higher volumes across all products

PORTFOLIO EXPANSION - Successful expansion of U.S. injectable portfolio with Evolysse™ launch

Company press release: ID:nBwbsydMha

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$89.22 mln
Q4 Net Income
$130,000
Q4 Gross Margin
65.7%
Q4 Adjusted Gross Margin
66.6%
Q4 Gross Profit
$59.29 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Evolus Inc is $14.00, about 226.3% above its March 2 closing price of $4.29

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)